UBS Reiterates Buy Rating on Jade Biosciences, Inc. (JBIO)
UBS maintains its buy rating for JBIO, setting a target price of $45.
Key Points
- UBS reiterated its buy rating on Jade Biosciences, Inc. (JBIO) with a price target of $45 on June 15, 2026.
- Shares of JBIO traded near $15.34 with a market cap of approximately $933.6 million.
- FMR LLC increased its holdings by 190,935 shares, now holding 7,085,423 shares valued at about $99.6 million.
On June 15, 2026, UBS reiterated its buy rating on Jade Biosciences, Inc. (NasdaqCM: JBIO) with a price target of $45. This move comes as the stock trades around $15.34. Jade Biosciences is a biotechnology company focused on developing therapies for autoimmune diseases.
What Changed in UBS's Jade Biosciences Position
UBS maintained its buy rating on Jade Biosciences, Inc. and set a target price of $45. This reiteration reflects the firm's continued confidence in the company's potential, although the prior target was not specified.
Other Institutional Activity in Jade Biosciences
Among Jade Biosciences' institutional investors, FMR LLC increased its holdings by 190,935 shares, bringing its total to 7,085,423 shares valued at about $99.6 million. Bellevue Group AG also added 160,399 shares, ending with 3,501,502 shares worth approximately $49.2 million. Meanwhile, Fairmount Funds Management LLC, RA Capital Management, L.P., and Venrock Adviser, LLC held steady with no changes in their positions.
Jade Biosciences, Inc. Stock Snapshot
Shares of Jade Biosciences, Inc. (NasdaqCM: JBIO) traded near $15.34. The company has a market cap of approximately $933.6 million. The stock's 52-week range spans from a low of $6.61 to a high of $28.00. Its 50-day moving average is around $21.20, while the 200-day moving average is about $14.48. Jade Biosciences maintains a strong liquidity position with a current ratio of 14.29 and a quick ratio of 13.96. The company has a low debt-to-equity ratio of 0.286.
Recent Earnings
Jade Biosciences, Inc. has not yet reached profitability, with an EPS of -$2.63 and a net margin of 0.0%. The company is expected to report its next earnings on August 13, 2026.
Insider Buying and Selling at Jade Biosciences, Inc.
On June 9, 2026, several insiders, including Lavelle Erin, Klein Lawrence Otto, and Fairmount Funds Management LLC, each acquired 34,843 shares. Additionally, Chief Financial Officer Bradford Dahms bought 37,813 shares on February 12, 2026.
Analysts Set New Price Targets
On June 15, 2026, UBS maintained its buy rating for Jade Biosciences with a $45 price target. Wedbush also reiterated its buy rating on June 2, 2026, with the same target. BTIG, on June 1, 2026, maintained a buy rating with a higher target of $74. HC Wainwright & Co. continued to support the stock with a buy rating and a $55 target on June 1, 2026. The consensus among seven analysts is a strong buy, with a mean target price of $49.
About Jade Biosciences, Inc.
Jade Biosciences, Inc. is a biotechnology company based in Waltham, Massachusetts. It focuses on developing therapies for inflammation and immunology indications, particularly for autoimmune diseases. The company is advancing its lead candidate, JADE101, through a phase 1 clinical trial. It also has preclinical programs, JADE201 and JADE-003. Jade Biosciences collaborates with Paragon Therapeutics, Inc. The company is led by CEO Mr. Tom Frohlich and employs approximately 55 people.
Bottom Line
UBS's reiterated buy rating and price target on Jade Biosciences reflect ongoing confidence in the company's potential within the biotechnology sector. Investors closely monitor these analyst actions for insights into the company's future prospects. As a reminder, these analyst ratings are based on past data and may not reflect the current market conditions.
See Also
This instant news alert was generated by automated narrative technology and financial data from EarningsIQ and public regulatory filings. It is for informational purposes only and is not financial advice.